Elevated PART1 is found in esophageal squamous cell carcinoma and promotes gefitinib resistance by competitively binding to miR-129 to facilitate Bcl-2 expression (Kang et al., 2018). The gene discussed is BCL2; the disease is esophageal squamous cell carcinoma.